Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Sciwind Closes $37 Million Round for Metabolic/Immunological Therapies

publication date: Feb 19, 2021

Hangzhou Sciwind closed a $37 Million series B financing led by LYFE Capital and joined by existing investors, Legend Capital and Haibang Venture Capital. Sciwind, known for its NASH projects, has started several clinical trials of candidates for metabolic and immunological diseases. It has completed a Phase I clinical study of a GLP-1 analogue weight loss treatment in Australia, and it plans to start China Phase II trials for therapies aimed at type II diabetes, obesity and non-alcoholic steatohepatitis (NASH). More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021